Site Search
Google Search
search button

Breaking News:

Secret Grand Jury Case on Friday, Reportedly Linked to Mueller Investigation, Blocked Reporters     - | -     Schumer Calls for Senate Vote After Texas Judge Calls Obamacare Unconstitutional      - | -     Saudis Claim Senate Interfering in Khashoggi Investigation as UN Demands Investigation      - | -     Trump Adviser Insists They'll Shut Down Government for Wall as Schumer Calls Out Trump for 'Temper Tantrum'      - | -     GOP Congressman Invokes 'The Deep State'
CRISPR Study Sends Biotech Stocks Tumbling
Get Business & Technology Alerts

viewsViews 1060
10 Jan 2018 06:09 AM EST

On Monday, a new paper had identified a possible barrier to using the revolutionary gene-editing tool CRISPR in humans. The news sent the stocks of all three major CRISPR biotech firms tumbling in premarket trading. They declined by as much as 11.9 percent.
In recent years, CRISPR has been credited with the potential power to correct any number of devastating diseases. Researchers have used it to cure mice of deadly genetic conditions like hemophilia B, Lou Gehrig’s disease, and Huntington’s disease. In the U.S., the first human CRISPR trials are slated to begin this year.

Post Your Comment
Excellent Very Good Good Fair Poor



Recently Posted Comments
FREE
AllMediaNY AllMediaNY AllMedaiNY